– Beehiiv Scales Email Ads with Expanded Sales Team
- Email newsletter platform Beehiiv is doubling its ad sales team as demand for email-native advertising inventory grows and creators look for passive revenue streams.
- The company, which caters to self-reliant newsletter creators, is building out its sales force from six to 12 people, according to Beehiiv co-founder and CEO Ben Helfin.
- "We're seeing a lot of interest from brands who are looking for alternatives to the customary display advertising ecosystem," Helfin said.
Beehiiv Doubles Ad Sales Team, Scaling Email Ads Business
Table of Contents
Email newsletter platform Beehiiv is doubling its ad sales team as demand for email-native advertising inventory grows and creators look for passive revenue streams.
The company, which caters to self-reliant newsletter creators, is building out its sales force from six to 12 people, according to Beehiiv co-founder and CEO Ben Helfin. The expansion comes as advertisers increasingly recognize the value of reaching engaged audiences directly in their inboxes.
“We’re seeing a lot of interest from brands who are looking for alternatives to the customary display advertising ecosystem,” Helfin said. “Email is a really unique channel because it’s permission-based and it’s a direct line to the consumer.”
Beehiiv’s ad sales team focuses on connecting advertisers with newsletters on its platform that meet their target audience criteria. The company takes a percentage of the ad revenue generated, providing a revenue share for both the advertiser and the newsletter creator.
Helfin said the company is seeing strong growth in ad revenue, with a 30% month-over-month increase in the last quarter of 2025. he attributes this growth to the increasing popularity of newsletters as a marketing channel and Beehiiv’s ability to offer advertisers access to highly engaged audiences.
“We’re really focused on building a lasting advertising ecosystem that benefits both advertisers and creators,” Helfin said. “We want to make it easy for brands to reach their target audiences in a way that’s respectful of the creator’s audience and doesn’t disrupt the reading experience.”
The company is also investing in new ad formats and targeting capabilities to further enhance the value of its advertising platform. Beehiiv recently launched a new sponsored content format that allows advertisers to create native-looking ads that blend seamlessly into the newsletter’s editorial content.
“We’re constantly experimenting with new ways to make email advertising more effective and engaging,” Helfin said. “we believe that email has the potential to be a really powerful advertising channel, and we’re committed to building the tools and infrastructure to make that happen.”
I am sorry, but the provided text only contains HTML `` and `` tags, representing stylesheet references and metadata. It does *not* include the actual HTML article body content. Therefore, I cannot fulfill your request to return the final HTML article body.
To get the article body, you would need to provide the HTML that *contains* the article’s text, headings, paragraphs, images, etc., within `
` tags.Beehiiv Doubles ad Sales Team, Scaling Email Ads business
The expansion comes as advertiser demand grows for email-native inventory and creators look for passive revenue streams.
Email newsletter platform Beehiiv is significantly expanding its ad sales team, doubling its size to meet growing demand for advertising within newsletters.
The company,which caters to independent creators and publishers,has seen a surge in interest from advertisers looking to tap into engaged email audiences. This demand is driven by the desire for more direct and less interruptive ad formats compared to traditional display advertising.
“We’re seeing a lot of advertisers who are realizing that email is a really valuable channel,” said Tyler Denk,co-founder and CEO of Beehiiv. “It’s a place where people are actively choosing to spend their time, and they’re much more receptive to advertising than they are on other platforms.”
Beehiiv’s ad sales team will focus on securing direct ad buys from brands, as well as expanding the platform’s programmatic advertising capabilities. Programmatic allows advertisers to automatically purchase ad space,increasing efficiency and reach.
For creators, offering ad space within their newsletters provides a new revenue stream beyond subscriptions and sponsorships. Beehiiv handles the ad sales and delivery, allowing creators to focus on content creation.
“creators are looking for ways to monetize their audiences without having to become ad sales experts,” Denk added. “We want to make it as easy as possible for them to earn revenue from their work.”
the growth of Beehiiv’s ad business reflects a broader trend in the creator economy, where platforms are increasingly focused on providing monetization tools for independent publishers.
The Inflation Reduction Act (IRA), signed into law on August 16, 2022, allows Medicare to negotiate prices for certain high-cost prescription drugs, a important shift in U.S. healthcare policy.This legislation aims to lower prescription drug costs for seniors and people with Medicare, while also investing in clean energy and healthcare affordability.
What Does the Inflation Reduction Act Do Regarding Prescription Drug Prices?
The Inflation Reduction Act empowers Medicare to directly negotiate the prices of some of the most expensive single-source drugs covered under Medicare Part B and Part D.this negotiation process began in 2023, with negotiated prices taking effect in 2026.
Prior to the IRA, Medicare was largely prohibited from negotiating drug prices with pharmaceutical companies.This meant that Medicare often paid higher prices for drugs than other countries. The IRA changes this by allowing the Centers for Medicare & Medicaid Services (CMS) to select drugs for negotiation based on factors like high Medicare spending and lack of generic or biosimilar competition. The initial 10 drugs selected for negotiation were announced in September 2023. CMS press release details these selections.
Example: In September 2023, CMS announced the first 10 drugs selected for price negotiation, including Eliquis (apixaban) for preventing blood clots, Jardiance (empagliflozin) for diabetes, and Xarelto (rivaroxaban) also for blood clots. The full list is available in a CMS fact sheet.
Which Drugs are Eligible for Negotiation?
not all drugs are eligible for negotiation under the IRA. The law specifies criteria for drug selection, focusing on those with the highest Medicare spending and limited competition.
Drugs are eligible if they meet the following criteria:
- Covered under Medicare Part B or Part D
- Lack generic or biosimilar competition
- Have been on the market for a certain period (generally 9 years for brand-name drugs, with exceptions for rare diseases)
- Meet specific spending thresholds – initially, drugs costing Medicare $3 billion or more annually. This threshold will decrease over time.
The CMS website provides a detailed clarification of the drug selection process,including the phased implementation schedule.
Detail: The number of drugs subject to negotiation will increase over time. In 2026, 10 drugs will be negotiated. This number will rise to 15 drugs in 2027, 20 drugs in 2028, and 25 drugs in 2029 and beyond. The full text of the IRA outlines this phased implementation.
What is the Impact on Medicare Beneficiaries?
The IRA is projected to significantly lower out-of-pocket costs for Medicare beneficiaries. Negotiated prices will be available to all Medicare beneficiaries, irrespective of their income or health status.
Beyond price negotiation, the IRA also includes other provisions to lower drug costs, such as:
- A $2,000 out-of-pocket cap on prescription drug costs for Medicare Part D beneficiaries, effective in 2025. KFF provides a detailed explainer on the out-of-pocket cap.
- Elimination of the 5% cost-sharing for the catastrophic phase of Medicare Part D, also effective in 2025.
- Free vaccines for Medicare beneficiaries.
Evidence: The Congressional Budget Office (CBO) estimates that the IRA will reduce federal drug spending by $101.4 billion over ten years (2022-2031). CBO report on the IRA’s impact provides these projections.
what are the Concerns and Challenges?
the pharmaceutical industry has expressed concerns that the IRA will stifle innovation by reducing their profits. they argue that lower prices will lead to less investment in research and growth of new drugs. Several pharmaceutical companies, including Merck and Johnson & Johnson, have filed lawsuits challenging the constitutionality of the drug price negotiation provisions.
Detail: The lawsuits argue that the IRA violates the Fifth Amendment’s Takings Clause, which prohibits the government from taking private property for public